| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2135970 | Hematology/Oncology and Stem Cell Therapy | 2010 | 7 Pages |
Abstract
When given with prednisone, treatment with docetaxel every three weeks does not improve survival, so the benefit of docetaxel-based therapy is not clear this high risk and poor prognostic group of patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Abd El Halim Mohamed Abu-Hamar, Saleh Mansour, Mohamed El Shebiney, Naser Mohamed Abd El Bary, Emad Sadaka, Alaa Maria,